TCTR20210201005已完成1 期
Safety and pharmacokinetic studies of Andrographis paniculata extracts in Thai healthy volunteers
Thailand Science Research and Innovation (TSRI)0 个研究点目标入组 48 人开始时间: 2021年2月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Subjects who are Thai male or female, aged 18 to 55 years (inclusive).
- •2. Subjects whose BMI is 18 30 kg/m2 (inclusive).
- •3. Subjects who are negative result of COVID 19 test.
- •4. Subjects who are healthy by medical history, physical examination, 12 lead ECG, and vital signs.
- •5. whose screening visit laboratory values of blood tests including complete blood count, hematocrit, glucose, blood urea nitrogen, serum creatinine, alkaline phosphatase, ALT, AST, total bilirubin, albumin, total cholesterol, triglycerides, HDL cholesterol, electrolytes, Hepatitis Bs antigen and anti HIV are within the normal range or showing no clinically significant abnormalities as confirmed by the clinical investigator.
- •6. For female subjects:
- •6.1 Female subject who is in childbearing potential must have urine pregnancy test negative and agrees to use an acceptable birth control method from visit 1 to the last visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device (IUD) and diaphragm with spermicial agent) or total abstinence from sexual intercourse from visit 1 to the last visit. Hormonal contraceptives are not acceptable.
- •6.2 Female subject who is in child bearing potential must agree not to become pregnant for the entire participation phase and must have a negative result for urine pregnancy test performing prior to dosing
- •6.3 Female subjects can be those with non childbearing potential which defined as female subjects with hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea).
- •7. Subjects are able to understand the requirements of the study and voluntarily sign and date an informed consent, approved by the Independent Ethic Committee (IEC)/ Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.
排除标准
- •1. Subjects who are with a history of COVID 19 positive test.
- •2. Subjects who are with a history/evidence of allergy or hypersensitivity to Andrographis paniculata.
- •3. Subjects who have a history of any illness that, in the opinion of the clinical investigator, might confound the result of the study or pose an additional risk in administrating AP capsule to the subjects. This may include but not limited to: a history of relevant drug or food allergies; history or cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements.
- •4. Subjects who are with a history of heavy smoking (more than 10 cigarettes per day) or moderate smoking (less than 10 cigarettes per day) and cannot omit smoking at least one day before the study and until the completion of the study phase.
- •5. Subjects who are with a history of alcoholic (more than 2 years) or moderate drinkers (more than 3 drinks per day one is equal to one unit of alcohol: one glass of wine, half pine of beer or one measure of spirit) or subjects who are with a history of any drug abuse.
- •6. Subjects who receive of any medical prescription within 14 days [especially any drug related to enzyme CYP450 inducer or inhibitor: CYP1A2 (theophylline)] before the first administration of AP capsule.
- •7. Female subjects who are pregnant or breast feeding.
- •8. Subjects who are participating in any investigational drug study or had been in any investigational drug study within 3 months prior to the screening visit.
研究者
相似试验
招募中
3 期
Efficacy and safety of an Andrographis capsule compared with standard therapy for the treatment of asymptomatic or mild COVID-19 without pneumonia : A double-blinded randomized-control trialasymptomatic or mild COVID-19 without pneumoniaSAR-CoV-2TCTR20211022002Health Systems Research Institute736
已完成
3 期
The efficacy and safety of Andrographis paniculata extract for the treatment of acute nonspecific upper respiratory tract infections: a randomized double-blind placebo controlled trialAcute nonspecific upper respiratory tract infections with one or more symptoms such as fever,sore throat,nasal congestion,dry infrequent cough and had modified Centor Score of 2 or less.Andrographis paniculataandrographolideacute nonspecific upper respiratory tract infectionspharyngitiscommon coldTCTR20170329002Department of Thai Traditional and Alternative Medicine829
已完成
2 期
Comparison efficacy and safety of Andrographis paniculata extract capsules and placebo in COVID-19 patients: Double blind randomized control trialCOVID-19 patient with asymptomatic and mild symptomatic. Progression score between 0-3. (Green color)COVID-19AndrographolideTCTR20210809004Thammasat university186
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy, safety and pharmacokinetics profile of nebulized Aztreonam Lysine (AZLI) for prevention of Gram negative pneumonia in heavily colonized mechanically ventilated patientsGram negative pneumonia in heavily colonized mechanically ventilated patientsMedDRA version: 20.0Level: LLTClassification code 10035725Term: Pneumonia NOSSystem Organ Class: 100000004862EUCTR2018-003865-32-ESAlejandro Rodriguez Oviedo - Critical Care Department – Hospital Universitario de Tarragona Joan XXIII20
尚未招募
1 期
The First Pharmacokinetic Study and Safety of of Oral Nano-emulsified Cannabidol (CBD-NE) in Healthy VolunteersCannabidiol (CBD) is a non-psychoactive extract from the hemp plant. CBD is involved in the body'TCTR20231114007Chakrabongse Aiewtrakoon72